Cargando…

Neoadjuvant Modified FOLFOX6 With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer: Final Results of the Chinese FOWARC Trial

PURPOSE: In the multicenter, open-label, phase III FOWARC trial, modified infusional fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus radiotherapy resulted in a higher pathologic complete response rate than fluorouracil plus radiotherapy in Chinese patients with locally advanced rectal canc...

Descripción completa

Detalles Bibliográficos
Autores principales: Deng, Yanhong, Chi, Pan, Lan, Ping, Wang, Lei, Chen, Weiqing, Cui, Long, Chen, Daoda, Cao, Jie, Wei, Hongbo, Peng, Xiang, Huang, Zonghai, Cai, Guanfu, Zhao, Ren, Huang, Zhongcheng, Xu, Lin, Zhou, Hongfeng, Wei, Yisheng, Zhang, Hao, Zheng, Jian, Huang, Yan, Zhou, Zhiyang, Cai, Yue, Kang, Liang, Huang, Meijin, Wu, Xiaojian, Peng, Junsheng, Ren, Donglin, Wang, Jianping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6881102/
https://www.ncbi.nlm.nih.gov/pubmed/31557064
http://dx.doi.org/10.1200/JCO.18.02309
_version_ 1783473882544472064
author Deng, Yanhong
Chi, Pan
Lan, Ping
Wang, Lei
Chen, Weiqing
Cui, Long
Chen, Daoda
Cao, Jie
Wei, Hongbo
Peng, Xiang
Huang, Zonghai
Cai, Guanfu
Zhao, Ren
Huang, Zhongcheng
Xu, Lin
Zhou, Hongfeng
Wei, Yisheng
Zhang, Hao
Zheng, Jian
Huang, Yan
Zhou, Zhiyang
Cai, Yue
Kang, Liang
Huang, Meijin
Wu, Xiaojian
Peng, Junsheng
Ren, Donglin
Wang, Jianping
author_facet Deng, Yanhong
Chi, Pan
Lan, Ping
Wang, Lei
Chen, Weiqing
Cui, Long
Chen, Daoda
Cao, Jie
Wei, Hongbo
Peng, Xiang
Huang, Zonghai
Cai, Guanfu
Zhao, Ren
Huang, Zhongcheng
Xu, Lin
Zhou, Hongfeng
Wei, Yisheng
Zhang, Hao
Zheng, Jian
Huang, Yan
Zhou, Zhiyang
Cai, Yue
Kang, Liang
Huang, Meijin
Wu, Xiaojian
Peng, Junsheng
Ren, Donglin
Wang, Jianping
author_sort Deng, Yanhong
collection PubMed
description PURPOSE: In the multicenter, open-label, phase III FOWARC trial, modified infusional fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus radiotherapy resulted in a higher pathologic complete response rate than fluorouracil plus radiotherapy in Chinese patients with locally advanced rectal cancer. Here, we report the final results. METHODS: Adults ages 18 to 75 years with stage II/III rectal cancer were randomly assigned (1:1:1) to five cycles of infusional fluorouracil (leucovorin 400 mg/m(2), fluorouracil 400 mg/m(2), and fluorouracil 2.4 g/m(2) over 48 hours) plus radiotherapy (46.0 to 50.4 Gy delivered in 23 to 25 fractions during cycles 2 to 4) followed by surgery and seven cycles of infusional fluorouracil, the same treatment plus intravenous oxaliplatin 85 mg/m(2) on day 1 of each cycle (mFOLFOX6), or four to six cycles of mFOLFOX6 followed by surgery and six to eight cycles of mFOLFOX6. The primary end point was 3-year disease-free survival (DFS). RESULTS: In total, 495 patients were randomly assigned to treatment. After a median follow-up of 45.2 months, DFS events were reported in 46, 39, and 46 patients in the fluorouracil plus radiotherapy, mFOLFOX6 plus radiotherapy, and mFOLFOX6 arms. In each arm, the probability of 3-year DFS was 72.9%, 77.2%, and 73.5% (P = .709 by the log-rank test), the 3-year probability of local recurrence after R0/1 resection was 8.0%, 7.0%, and 8.3% (P = .873 by the log-rank test), and the 3-year overall survival rate was 91.3%, 89.1%, and 90.7% (P = .971 by log-rank test), respectively. CONCLUSION: mFOLFOX6, with or without radiation, did not significantly improve 3-year DFS versus fluorouracil with radiation in patients with locally advanced rectal cancer. No significant difference in outcomes was found between mFOLFOX6 without radiotherapy and fluorouracil with radiotherapy, which requires additional investigation of the role of radiotherapy in these regimens.
format Online
Article
Text
id pubmed-6881102
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher American Society of Clinical Oncology
record_format MEDLINE/PubMed
spelling pubmed-68811022020-12-01 Neoadjuvant Modified FOLFOX6 With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer: Final Results of the Chinese FOWARC Trial Deng, Yanhong Chi, Pan Lan, Ping Wang, Lei Chen, Weiqing Cui, Long Chen, Daoda Cao, Jie Wei, Hongbo Peng, Xiang Huang, Zonghai Cai, Guanfu Zhao, Ren Huang, Zhongcheng Xu, Lin Zhou, Hongfeng Wei, Yisheng Zhang, Hao Zheng, Jian Huang, Yan Zhou, Zhiyang Cai, Yue Kang, Liang Huang, Meijin Wu, Xiaojian Peng, Junsheng Ren, Donglin Wang, Jianping J Clin Oncol ORIGINAL REPORTS PURPOSE: In the multicenter, open-label, phase III FOWARC trial, modified infusional fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus radiotherapy resulted in a higher pathologic complete response rate than fluorouracil plus radiotherapy in Chinese patients with locally advanced rectal cancer. Here, we report the final results. METHODS: Adults ages 18 to 75 years with stage II/III rectal cancer were randomly assigned (1:1:1) to five cycles of infusional fluorouracil (leucovorin 400 mg/m(2), fluorouracil 400 mg/m(2), and fluorouracil 2.4 g/m(2) over 48 hours) plus radiotherapy (46.0 to 50.4 Gy delivered in 23 to 25 fractions during cycles 2 to 4) followed by surgery and seven cycles of infusional fluorouracil, the same treatment plus intravenous oxaliplatin 85 mg/m(2) on day 1 of each cycle (mFOLFOX6), or four to six cycles of mFOLFOX6 followed by surgery and six to eight cycles of mFOLFOX6. The primary end point was 3-year disease-free survival (DFS). RESULTS: In total, 495 patients were randomly assigned to treatment. After a median follow-up of 45.2 months, DFS events were reported in 46, 39, and 46 patients in the fluorouracil plus radiotherapy, mFOLFOX6 plus radiotherapy, and mFOLFOX6 arms. In each arm, the probability of 3-year DFS was 72.9%, 77.2%, and 73.5% (P = .709 by the log-rank test), the 3-year probability of local recurrence after R0/1 resection was 8.0%, 7.0%, and 8.3% (P = .873 by the log-rank test), and the 3-year overall survival rate was 91.3%, 89.1%, and 90.7% (P = .971 by log-rank test), respectively. CONCLUSION: mFOLFOX6, with or without radiation, did not significantly improve 3-year DFS versus fluorouracil with radiation in patients with locally advanced rectal cancer. No significant difference in outcomes was found between mFOLFOX6 without radiotherapy and fluorouracil with radiotherapy, which requires additional investigation of the role of radiotherapy in these regimens. American Society of Clinical Oncology 2019-12-01 2019-09-26 /pmc/articles/PMC6881102/ /pubmed/31557064 http://dx.doi.org/10.1200/JCO.18.02309 Text en © 2019 by American Society of Clinical Oncology https://creativecommons.org/licenses/by-nc-nd/4.0/ Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: https://creativecommons.org/licenses/by-nc-nd/4.0/
spellingShingle ORIGINAL REPORTS
Deng, Yanhong
Chi, Pan
Lan, Ping
Wang, Lei
Chen, Weiqing
Cui, Long
Chen, Daoda
Cao, Jie
Wei, Hongbo
Peng, Xiang
Huang, Zonghai
Cai, Guanfu
Zhao, Ren
Huang, Zhongcheng
Xu, Lin
Zhou, Hongfeng
Wei, Yisheng
Zhang, Hao
Zheng, Jian
Huang, Yan
Zhou, Zhiyang
Cai, Yue
Kang, Liang
Huang, Meijin
Wu, Xiaojian
Peng, Junsheng
Ren, Donglin
Wang, Jianping
Neoadjuvant Modified FOLFOX6 With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer: Final Results of the Chinese FOWARC Trial
title Neoadjuvant Modified FOLFOX6 With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer: Final Results of the Chinese FOWARC Trial
title_full Neoadjuvant Modified FOLFOX6 With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer: Final Results of the Chinese FOWARC Trial
title_fullStr Neoadjuvant Modified FOLFOX6 With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer: Final Results of the Chinese FOWARC Trial
title_full_unstemmed Neoadjuvant Modified FOLFOX6 With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer: Final Results of the Chinese FOWARC Trial
title_short Neoadjuvant Modified FOLFOX6 With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer: Final Results of the Chinese FOWARC Trial
title_sort neoadjuvant modified folfox6 with or without radiation versus fluorouracil plus radiation for locally advanced rectal cancer: final results of the chinese fowarc trial
topic ORIGINAL REPORTS
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6881102/
https://www.ncbi.nlm.nih.gov/pubmed/31557064
http://dx.doi.org/10.1200/JCO.18.02309
work_keys_str_mv AT dengyanhong neoadjuvantmodifiedfolfox6withorwithoutradiationversusfluorouracilplusradiationforlocallyadvancedrectalcancerfinalresultsofthechinesefowarctrial
AT chipan neoadjuvantmodifiedfolfox6withorwithoutradiationversusfluorouracilplusradiationforlocallyadvancedrectalcancerfinalresultsofthechinesefowarctrial
AT lanping neoadjuvantmodifiedfolfox6withorwithoutradiationversusfluorouracilplusradiationforlocallyadvancedrectalcancerfinalresultsofthechinesefowarctrial
AT wanglei neoadjuvantmodifiedfolfox6withorwithoutradiationversusfluorouracilplusradiationforlocallyadvancedrectalcancerfinalresultsofthechinesefowarctrial
AT chenweiqing neoadjuvantmodifiedfolfox6withorwithoutradiationversusfluorouracilplusradiationforlocallyadvancedrectalcancerfinalresultsofthechinesefowarctrial
AT cuilong neoadjuvantmodifiedfolfox6withorwithoutradiationversusfluorouracilplusradiationforlocallyadvancedrectalcancerfinalresultsofthechinesefowarctrial
AT chendaoda neoadjuvantmodifiedfolfox6withorwithoutradiationversusfluorouracilplusradiationforlocallyadvancedrectalcancerfinalresultsofthechinesefowarctrial
AT caojie neoadjuvantmodifiedfolfox6withorwithoutradiationversusfluorouracilplusradiationforlocallyadvancedrectalcancerfinalresultsofthechinesefowarctrial
AT weihongbo neoadjuvantmodifiedfolfox6withorwithoutradiationversusfluorouracilplusradiationforlocallyadvancedrectalcancerfinalresultsofthechinesefowarctrial
AT pengxiang neoadjuvantmodifiedfolfox6withorwithoutradiationversusfluorouracilplusradiationforlocallyadvancedrectalcancerfinalresultsofthechinesefowarctrial
AT huangzonghai neoadjuvantmodifiedfolfox6withorwithoutradiationversusfluorouracilplusradiationforlocallyadvancedrectalcancerfinalresultsofthechinesefowarctrial
AT caiguanfu neoadjuvantmodifiedfolfox6withorwithoutradiationversusfluorouracilplusradiationforlocallyadvancedrectalcancerfinalresultsofthechinesefowarctrial
AT zhaoren neoadjuvantmodifiedfolfox6withorwithoutradiationversusfluorouracilplusradiationforlocallyadvancedrectalcancerfinalresultsofthechinesefowarctrial
AT huangzhongcheng neoadjuvantmodifiedfolfox6withorwithoutradiationversusfluorouracilplusradiationforlocallyadvancedrectalcancerfinalresultsofthechinesefowarctrial
AT xulin neoadjuvantmodifiedfolfox6withorwithoutradiationversusfluorouracilplusradiationforlocallyadvancedrectalcancerfinalresultsofthechinesefowarctrial
AT zhouhongfeng neoadjuvantmodifiedfolfox6withorwithoutradiationversusfluorouracilplusradiationforlocallyadvancedrectalcancerfinalresultsofthechinesefowarctrial
AT weiyisheng neoadjuvantmodifiedfolfox6withorwithoutradiationversusfluorouracilplusradiationforlocallyadvancedrectalcancerfinalresultsofthechinesefowarctrial
AT zhanghao neoadjuvantmodifiedfolfox6withorwithoutradiationversusfluorouracilplusradiationforlocallyadvancedrectalcancerfinalresultsofthechinesefowarctrial
AT zhengjian neoadjuvantmodifiedfolfox6withorwithoutradiationversusfluorouracilplusradiationforlocallyadvancedrectalcancerfinalresultsofthechinesefowarctrial
AT huangyan neoadjuvantmodifiedfolfox6withorwithoutradiationversusfluorouracilplusradiationforlocallyadvancedrectalcancerfinalresultsofthechinesefowarctrial
AT zhouzhiyang neoadjuvantmodifiedfolfox6withorwithoutradiationversusfluorouracilplusradiationforlocallyadvancedrectalcancerfinalresultsofthechinesefowarctrial
AT caiyue neoadjuvantmodifiedfolfox6withorwithoutradiationversusfluorouracilplusradiationforlocallyadvancedrectalcancerfinalresultsofthechinesefowarctrial
AT kangliang neoadjuvantmodifiedfolfox6withorwithoutradiationversusfluorouracilplusradiationforlocallyadvancedrectalcancerfinalresultsofthechinesefowarctrial
AT huangmeijin neoadjuvantmodifiedfolfox6withorwithoutradiationversusfluorouracilplusradiationforlocallyadvancedrectalcancerfinalresultsofthechinesefowarctrial
AT wuxiaojian neoadjuvantmodifiedfolfox6withorwithoutradiationversusfluorouracilplusradiationforlocallyadvancedrectalcancerfinalresultsofthechinesefowarctrial
AT pengjunsheng neoadjuvantmodifiedfolfox6withorwithoutradiationversusfluorouracilplusradiationforlocallyadvancedrectalcancerfinalresultsofthechinesefowarctrial
AT rendonglin neoadjuvantmodifiedfolfox6withorwithoutradiationversusfluorouracilplusradiationforlocallyadvancedrectalcancerfinalresultsofthechinesefowarctrial
AT wangjianping neoadjuvantmodifiedfolfox6withorwithoutradiationversusfluorouracilplusradiationforlocallyadvancedrectalcancerfinalresultsofthechinesefowarctrial